There's been some reports of Guillain-Barré syndrome in older adults who got the vaccines. But health officials still ...
The first respiratory syncytial virus (RSV) vaccine has been approved for adults aged 50 to 59 years who are at increased ...
The U.S. Food and Drug Administration on Friday has for the first time approved the use of a respiratory syncytial virus (RSV ...
GSK plc (GSK, GSK.L) announced Monday that the US Food and Drug Administration has approved Arexvy, Respiratory Syncytial Virus or ...
US FDA approves GSK’s respiratory syncytial virus vaccine, Arexvy for adults aged 50-59 at increased risk: London, UK Monday, June 10, 2024, 10:00 Hrs [IST] GSK plc announced th ...
The FDA on Friday approved a label expansion for GSK’s respiratory syncytial virus vaccine Arexvy, allowing its use in adults ...
In the US, the vaccine is currently approved for use in adults aged 60 and older and recommended by CDC/ACIP using shared clinical decision-making ... In May 2023, the FDA approved GSK’s RSV vaccine ...
(Reuters) -The U.S. Food and Drug Administration approved the expanded use of GSK’s respiratory syncytial virus (RSV ...
Moderna has secured approval from the US Food and Drug Administration (FDA) for its mRNA-based respiratory syncytial virus ...
The company said it plans to conduct two separate trials testing Gardasil 9 in men and women 16-26 years old to examine whether a single dose of the vaccine ... severe RSV disease through their second ...
The U.S. Food and Drug Administration approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on ...
The US Food and Drug Administration has approved another vaccine to help protect older people from respiratory syncytial ...